Quality of Life and Pain Outcomes Data from Ph 3 PANOVA-3 Trial of Tumor Treating Fields for Pancreatic Cancer Published

“This publication in JAMA Network Open is an important step in providing the results from PANOVA-3 to the oncology community through a peer-reviewed resource,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The results from the PANOVA-3 trial demonstrated the efficacy of Tumor Treating Fields therapy in locally advanced pancreatic cancer. We also evaluated and saw a positive and clinically meaningful effect from treatment with Tumor Treating Fields on pain, which can significantly affect patients’ quality of life. We believe these results can help inform clinicians and patients as they make treatment decisions.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib